<p>2025 年 5 月 21 日- 下午 2:52</p>
<p><em>Navidea Biopharmaceuticals, Inc. 延长实施反向股票拆分的截止日期</em></p>
<p>俄亥俄州哥伦布市 --（商业新闻）--Navidea Biopharmaceuticals, Inc.（OTC: NAVB）（“Navidea” 或 “公司”）是一家专注于开发精准免疫诊断剂和免疫治疗药物的生物制药公司，今天宣布延长其实施反向股票拆分的授权，比例高达 1 股对 50,000 股。</p>
<p>公司最初在 2024 年 7 月 8 日举行的特别会议上获得股东批准，修订其公司章程以授权反向股票拆分，比例高达 1 股对 50,000 股。该授权最初定于 2025 年 7 月 8 日到期，现在已延长两年至 2027 年 7 月 8 日。该延长获得了公司董事会的批准，并通过大多数股东的书面行动确认。</p>
<p><em>执行反向股票拆分的决定，包括时机和具体比例，仍由 Navidea 的董事会自行决定。</em></p>
<p><em>“考虑反向股票拆分的理由是多方面的，” Navidea 首席财务官 Craig A. Dais 表示。“随着我们继续评估战略合作伙伴关系和其他融资机会，以推进我们的药物开发目标，简化公司的资本结构至关重要。此外，减少我们普通股的记录持有者数量是保持在美国证券交易委员会（SEC）阈值以下的关键步骤，否则将需要持续的公开报告，这会产生显著成本。如果实施，反向股票拆分将有助于实现这一目标。”</em></p>
<p>关于 Navidea</p>
<p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家专注于开发精准免疫诊断剂和免疫治疗药物的生物制药公司。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并实现更好的诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体的能力。Manocept 平台作为 Tc99m tilmanocept 的分子基础，这是 Navidea 基于该平台开发和商业化的首个产品。Navidea 的战略是通过推出新产品和推进公司的产品管道，通过全球合作和商业化努力实现卓越的增长和股东回报。有关更多信息，请访问 www.navidea.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。我们在很大程度上基于当前的预期和关于影响我们业务财务状况的未来事件和财务趋势的预测来制定这些前瞻性声明。前瞻性声明包括我们对待决诉讼和其他事项的预期。这些前瞻性声明受到多种风险、不确定性和假设的影响，包括但不限于：我们经营亏损的历史和未来盈利能力的不确定性；任何待决诉讼的最终结果；我们成功完成药物候选者的研究和进一步开发的能力；获得药物候选者的监管批准的时间、成本和不确定性；我们成功商业化药物候选者的能力；对特许权使用费和补助收入的依赖；我们实施增长战略的能力；我们业务的预期趋势；我们有限的产品线和分销渠道；技术进步和新竞争产品的开发；我们保持有效的财务报告内部控制的能力；当前冠状病毒大流行的影响；以及我们最近的 10-K 表格年报和其他 SEC 文件中详细列出的其他风险因素。我们敦促您仔细审查和考虑我们在 SEC 文件中找到的披露，这些文件可在 http://www.sec.gov 或 http://ir.navidea.com 获取。</p>
<p>投资者被敦促考虑包含 “将”、“可能”、“能够”、“应该”、“计划”、“继续”、“设计”、“目标”、“预测”、“未来”、“相信”、“打算”、“期望”、“预期”、“估计”、“项目” 等词语的声明，以及这些词语的否定形式或其他类似词语，作为不确定的前瞻性声明。</p>
<p>您被警告不要对任何前瞻性声明过度依赖，这些声明可能会被证明是错误的。我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，在本报告日期之后。鉴于这些风险和不确定性，本报告中讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果有重大差异。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ"/></p>
<p>查看商业新闻网站上的源版本：https://www.businesswire.com/news/home/20250520421964/en/</p>
<p><strong>投资者关系联系人</strong></p>
<p>Navidea Biopharmaceuticals, Inc.</p>
<p>首席财务官 Craig A. Dais</p>
<p>cdais@navidea.com</p>
<p>(614)-822-2322</p>
<p>来源：Navidea Biopharmaceuticals, Inc.</p>

Navidea生物制药

NAVBQ

<p>Navidea 生物制药公司已延长其实施最多 1 股换 50,000 股的反向股票拆分的授权，直到 2027 年 7 月 8 日。此决定经过董事会和股东的批准，旨在简化公司的资本结构，并减少登记持有者的数量，以避免显著的公共报告成本。拆分的具体时间和比例将由董事会决定。Navidea 专注于开发精准免疫诊断剂和免疫治疗药物</p>

<p>05/21/2025 - 02:52 PM</p>
<div class="lb-trans"><p>2025 年 5 月 21 日- 下午 2:52</p>
</div><p><em>Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split</em></p>
<div class="lb-trans"><p><em>Navidea Biopharmaceuticals, Inc. 延长实施反向股票拆分的截止日期</em></p>
</div><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares.</p>
<div class="lb-trans"><p>俄亥俄州哥伦布市 --（商业新闻）--Navidea Biopharmaceuticals, Inc.（OTC: NAVB）（“Navidea” 或 “公司”）是一家专注于开发精准免疫诊断剂和免疫治疗药物的生物制药公司，今天宣布延长其实施反向股票拆分的授权，比例高达 1 股对 50,000 股。</p>
</div><p>The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, has now been extended by two years to July 8, 2027. The extension was approved by the Company’s Board of Directors and confirmed through written action by a majority of its shareholders.</p>
<div class="lb-trans"><p>公司最初在 2024 年 7 月 8 日举行的特别会议上获得股东批准，修订其公司章程以授权反向股票拆分，比例高达 1 股对 50,000 股。该授权最初定于 2025 年 7 月 8 日到期，现在已延长两年至 2027 年 7 月 8 日。该延长获得了公司董事会的批准，并通过大多数股东的书面行动确认。</p>
</div><p><em>The decision to execute a reverse stock split, including the timing and specific ratio, remains at the discretion of Navidea’s Board of Directors.</em></p>
<div class="lb-trans"><p><em>执行反向股票拆分的决定，包括时机和具体比例，仍由 Navidea 的董事会自行决定。</em></p>
</div><p><em>“The rationale behind considering a reverse stock split is multifaceted,” said Craig A. Dais, Chief Financial Officer of Navidea. “As we continue to evaluate strategic partnerships and other funding opportunities to advance our pharmaceutical development objectives, it is essential to simplify the Company’s capitalization table. Additionally, reducing the number of record holders of our common stock is a key step toward staying below the SEC threshold that would otherwise require ongoing public reporting, which entails significant costs. If implemented, the reverse stock split would help achieve this objective.”</em></p>
<div class="lb-trans"><p><em>“考虑反向股票拆分的理由是多方面的，” Navidea 首席财务官 Craig A. Dais 表示。“随着我们继续评估战略合作伙伴关系和其他融资机会，以推进我们的药物开发目标，简化公司的资本结构至关重要。此外，减少我们普通股的记录持有者数量是保持在美国证券交易委员会（SEC）阈值以下的关键步骤，否则将需要持续的公开报告，这会产生显著成本。如果实施，反向股票拆分将有助于实现这一目标。”</em></p>
</div><p>About Navidea</p>
<div class="lb-trans"><p>关于 Navidea</p>
</div><p>Navidea Biopharmaceuticals, Inc. (OTC: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, visit www.navidea.com.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.（OTC: NAVB）是一家专注于开发精准免疫诊断剂和免疫治疗药物的生物制药公司。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并实现更好的诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体的能力。Manocept 平台作为 Tc99m tilmanocept 的分子基础，这是 Navidea 基于该平台开发和商业化的首个产品。Navidea 的战略是通过推出新产品和推进公司的产品管道，通过全球合作和商业化努力实现卓越的增长和股东回报。有关更多信息，请访问 www.navidea.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our history of operating losses and uncertainty of future profitability; the final outcome of any pending litigation; our ability to successfully complete research and further development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; our ability to maintain effective internal control over financial reporting; the impact of the current coronavirus pandemic; and other risk factors detailed in our most recent Annual Report on Form 10-K and other SEC filings. You are urged to carefully review and consider the disclosures found in our SEC filings, which are available at http://www.sec.gov or at http://ir.navidea.com.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1933 年证券法第 27A 条及 1934 年证券交易法第 21E 条的定义的前瞻性声明。我们在很大程度上基于当前的预期和关于影响我们业务财务状况的未来事件和财务趋势的预测来制定这些前瞻性声明。前瞻性声明包括我们对待决诉讼和其他事项的预期。这些前瞻性声明受到多种风险、不确定性和假设的影响，包括但不限于：我们经营亏损的历史和未来盈利能力的不确定性；任何待决诉讼的最终结果；我们成功完成药物候选者的研究和进一步开发的能力；获得药物候选者的监管批准的时间、成本和不确定性；我们成功商业化药物候选者的能力；对特许权使用费和补助收入的依赖；我们实施增长战略的能力；我们业务的预期趋势；我们有限的产品线和分销渠道；技术进步和新竞争产品的开发；我们保持有效的财务报告内部控制的能力；当前冠状病毒大流行的影响；以及我们最近的 10-K 表格年报和其他 SEC 文件中详细列出的其他风险因素。我们敦促您仔细审查和考虑我们在 SEC 文件中找到的披露，这些文件可在 http://www.sec.gov 或 http://ir.navidea.com 获取。</p>
</div><p>Investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.</p>
<div class="lb-trans"><p>投资者被敦促考虑包含 “将”、“可能”、“能够”、“应该”、“计划”、“继续”、“设计”、“目标”、“预测”、“未来”、“相信”、“打算”、“期望”、“预期”、“估计”、“项目” 等词语的声明，以及这些词语的否定形式或其他类似词语，作为不确定的前瞻性声明。</p>
</div><p>You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward- looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.</p>
<div class="lb-trans"><p>您被警告不要对任何前瞻性声明过度依赖，这些声明可能会被证明是错误的。我们没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，在本报告日期之后。鉴于这些风险和不确定性，本报告中讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果有重大差异。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA1MjA0MjE5NjRyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250520421964r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250520421964/en/</p>
<div class="lb-trans"><p>查看商业新闻网站上的源版本：https://www.businesswire.com/news/home/20250520421964/en/</p>
</div><p><strong>Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人</strong></p>
</div><p>Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.</p>
</div><p>Craig A. Dais, Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官 Craig A. Dais</p>
</div><p>cdais@navidea.com</p>
<div class="lb-trans"><p>cdais@navidea.com</p>
</div><p>(614)-822-2322</p>
<div class="lb-trans"><p>(614)-822-2322</p>
</div><p>Source: Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Navidea Biopharmaceuticals, Inc.</p>
</div>

Navidea 生物制药公司宣布延长实施反向股票分割的授权 | NAVB 股票新闻